The stock of Kadmon Holdings Inc (NYSE:KDMN) reached all time low today, Oct, 13 and still has $5.42 target or 14.00% below today’s $6.30 share price. This indicates more downside for the $285.24M company. This technical setup was reported by Barchart.com. If the $5.42 PT is reached, the company will be worth $39.93M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 51,479 shares traded hands. Kadmon Holdings Inc (NYSE:KDMN) has risen 6.00% since September 13, 2016 and is uptrending. It has underperformed by 1.52% the S&P500.
Kadmon Holdings Inc (NYSE:KDMN) Ratings Coverage
Out of 4 analysts covering Kadmon Holdings (NYSE:KDMN), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Kadmon Holdings has been the topic of 4 analyst reports since August 22, 2016 according to StockzIntelligence Inc. Jefferies initiated Kadmon Holdings Inc (NYSE:KDMN) rating on Monday, August 22. Jefferies has “Buy” rating and $12 price target. On Monday, August 22 the stock rating was initiated by Citigroup with “Neutral”. JMP Securities initiated Kadmon Holdings Inc (NYSE:KDMN) on Monday, August 22 with “Outperform” rating. The firm has “Buy” rating by H.C. Wainwright given on Monday, August 22.
According to Zacks Investment Research, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York.”
More important recent Kadmon Holdings Inc (NYSE:KDMN) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on June 17, 2016, also Marketwatch.com published article titled: “Sam Waksal’s Kadmon Holdings prices IPO”, Marketwatch.com published: “Kadmon Holdings trading below $12 issue price in market debut” on July 27, 2016. More interesting news about Kadmon Holdings Inc (NYSE:KDMN) was released by: Businesswire.com and their article: “Kadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Glioblastoma” with publication date: August 29, 2016.
KDMN Company Profile
Kadmon Holdings, Inc., formerly Kadmon Holdings, LLC, is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of small molecules and biologics. The Firm is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. The Company’s product candidates include KD025, Tesevatinib in Oncology, Tesevatinib in polycystic kidney disease (PKD) and KD034. It also offers tablets and capsules, such as Ribasphere RibaPak, Ribasphere tablets, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.